Development of novel drug for obesity targeting endoplasmic reticulum stress
| Project/Area Number |
22590100
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Drug development chemistry
|
|---|
| Research Institution | Hiroshima University |
|---|
Principal Investigator |
OZAWA Koichiro 広島大学, 医歯薬保健学研究院, 教授 (10211822)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TAKEDA Kei 広島大学, 大学院・医歯薬保健学研究院, 教授 (30135032)
HOSOI Toru 広島大学, 大学院・医歯薬保健学研究院, 講師 (40379889)
|
|---|
| Project Period (FY) |
2010 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2012: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2011: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2010: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | レプチン抵抗性 / 小胞体ストレス / レプチン / 抗肥満薬 / 肥満 |
|---|
| Research Abstract |
Obesity is one of major risk factor of metabolic syndrome. Previous study indicated that endoplasmic reticulum (ER) stress may be involved in development of “leptin resistance”, an insensitivity of anti-obesity hormone leptin. In the present study, we aimed to develop novel brain-transitional drug for attenuating ER stress and “leptin resistance”, based on the structure of drug which we identifiedpreviously. We analyzed pharmacological property of this drug. Moreover, we investigated whether this drug has anti-obesity action using mice model of high-fat diet-induced obesity.
|
Report
(4 results)
Research Products
(36 results)
